Forty Seven and Rocket Pharmaceuticals Announce Research Collaboration for Fanconi AnemiaGlobeNewsWire • 03/11/20
Gilead Sciences' Acquisition Of Forty Seven Was A Wise Move, CD47 Space Is Key Future Cancer TargetSeeking Alpha • 03/09/20
Gilead Sciences Acquiring Cancer-Focused Biotech Forty Seven for $4.9 BillionThe Motley Fool • 03/02/20
Why Gilead Sciences, Forty Seven, and Trillium Therapeutics Are Moving Higher TodayThe Motley Fool • 03/02/20
Biotech company Forty Seven surges 30% after hours on report of Gilead interestMarket Watch • 02/28/20
Forty Seven Validates CD47 With 'Don't Eat Me' Tech, Pivotal Studies To Be Initiated In 2020Seeking Alpha • 01/19/20